Clinical trials: PAH
Pulmonary Artery Hypertension
Vascular Subphenotypes of Lung Disease in HIV & COPD
This study is looking for high blood pressure in the lungs (Pulmonary artery hypertension PAH) in HIV and COPD patients.
- Trial name
- VAST (NCT01581086)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Pittsburgh
Pulmonary Arterial Hypertension
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
The AC-055-302/SERAPHIN study will be an event-driven Phase III study, comparing two different doses of macitentan (ACT-064992) (3 and 10 mg) vs placebo in patients with symptomatic PAH.
- Trial name
- SERAPHIN (NCT00660179)
- Testing
- macitentan (ACT-064992)
- Where
- 153 sites in United States, Argentina and 36 more
- Volunteers
- 742 people
- Sponsor
- Actelion
Pulmonary Hypertension (Idiopathic, Familial or Anorexigen-associated)
Dichloroacetate (DCA) for the Treatment of Pulmonary Arterial Hypertension
Hypothesis: The small molecule and metabolic modulator Dichloroacetate (DCA) is safe, tolerated as a potential therapy in patients with moderate or severe Pulmonary Arterial Hypertension (PAH).
- Trial name
- NCT01083524
- Testing
- Dichloroacetate Sodium
- Where
- 2 sites in Canada, United Kingdom
- Volunteers
- 30 people
- Sponsor
- University of Alberta
Hypertension, Pulmonary
Interaction Study in Patients With Pulmonary Hypertension and Stable Treatment of Sildenafil 20 mg TID
This study is to demonstrate the safety, tolerability, pharmakokinetic and pharmacodynamic effect of BAY63-2521 in patients with pulmonary hypertension and stable treatment of sildenafil 20 mg.
- Trial name
- NCT00680654
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 5 sites in Germany
- Volunteers
- 7 people
- Sponsor
- Bayer
Pulmonary Artery Hypertension
A Study of Stellate Ganglion Block and / or Reserpine in Group 2 Pulmonary Hypertension
Pulmonary hypertension Group 2 (PH 2) associated with left-sided heart disease is relatively common, is associated with a poor prognosis, and unfortunately there are no proven medical treatments beyond attempts at correcting the…
- Trial name
- NCT02684786
- Testing
- reserpine, stellate ganglion block, lidocaine
- Where
- United States
- Sponsor
- Mayo Clinic
Pulmonary Arterial Hypertension
Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Patients With Pulmonary Arterial Hypertension
This study enrolls patients with pulmonary arterial hypertension (PAH) treated with inhaled treprostinil. During the study, the treatment with inhaled treprostinil will be tapered off and simultaneously replaced with an oral…
- Trial name
- TRANSIT-1 (NCT02471183)
- Testing
- Selexipag
- Where
- 15 sites in United States
- Volunteers
- 34 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
(-)-Epicatechin and Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a progressive disease that results in severe activity limitation and death. There are few treatments for PAH and the available medications are expensive, difficult to administer and have…
- Trial name
- NCT01880866
- Testing
- (-)-Epicatechin
- Where
- United States
- Sponsor
- University of California, San Francisco
Systemic Sclerosis, Pulmonary Hypertension
Evaluation of Pulmonary Doppler Signals in Patients With Systemic Sclerosis(SSc)
Doppler signals can be recorded from the lung parenchyma by means of a pulsed Doppler ultrasound system incorporating a special signal processing package- the Transthoracic Parametric Doppler (TPD) (Echosense Ltd., Haifa…
- Trial name
- NCT02278445
- Testing
- Doppler ultrasound, Transthoracic Parametric Doppler (TPD) (Echosense Ltd., Haifa, Israel)
- Where
- Israel
- Sponsor
- Echosense Ltd.
Pulmonary Arterial Hypertension
The Expression and Significance of MiRNA
It is not always known what causes PAH or what the best treatment is. The doctors doing this study would like to understand more about why some people develop PAH and other do not.
- Trial name
- NCT00806312
- Where
- United States
- Volunteers
- 207 people
- Sponsor
- Megan Ballinger
Hypertension, Pulmonary
A Clinical Study of MK-7962 in Chinese Participants With Pulmonary Arterial Hypertension (MK-7962-022)
Researchers are looking for ways to treat people with a type of high blood pressure in the lungs called pulmonary arterial hypertension (PAH).
- Trial name
- NCT07899905
- Testing
- Sotatercept
- Volunteers
- 40 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Arterial Hypertension
Safety and Efficacy of Nebulized Nitroglycerin in Pulmonary Arterial Hypertension
The 6th World Symposium on Pulmonary Hypertension, pre-capillary pulmonary hypertension (PH) has been defined as mean pulmonary arterial pressure (mPAP) >20 mm Hg with a pulmonary arterial wedge pressure (PAWP) ≤15 mm Hg and…
- Trial name
- NCT07214129
- Testing
- Nebulized nitroglycerin
- Where
- Egypt
- Volunteers
- 20 people
- Sponsor
- Mansoura University
Pulmonary Arterial Hypertension
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
This open-label extension study will evaluate the long-term safety, tolerability and efficacy of orally inhaled seralutinib in subjects who have completed a previous seralutinib study
- Trial name
- NCT06274801
- Testing
- Seralutinib, Gereic Dry Powder Inhaler
- Where
- 120 sites in United States, Argentina and 28 more
- Volunteers
- 330 people
- Sponsor
- Gossamer Bio USA, Inc.
Interstitial Lung Disease
The Six Minute Walk Test: Influence of Instruction on Results
Two - four 6MWT performed according to ATS standards. Each walk however had specifically altered wording and coaching performed in random order to determine differences in outcomes. One walk was done in the standard ATS fashion.
- Trial name
- NCT01789996
- Testing
- alternative six minute walk test, Standard six minute walk test
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Inova Health Care Services
Pulmonary Arterial Hypertension
Dose-Finding, Safety, Pharmacodynamic Effect Study of Sodium Nitrite Inhalation Solution in Normal, Healthy Volunteers
This study is designed to investigate the safety and tolerability of AIR001 Inhalation Solution when administered under conditions of hypoxia and to identify dose levels of drug resulting in a reduction in pulmonary arterial…
- Trial name
- AIR001-CS02 (NCT00814645)
- Testing
- Sodium Nitrite Inhalation Solution
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Aires Pharmaceuticals, Inc.
Pulmonary Arterial Hypertension
Central China Congenital Heart Disease Associated Pulmonary Arterial Hypertension Cohort Study
The study will recruit and follow up patients for five years patients newly diagnosed with congenital heart disease associated pulmonary arterial hypertension(CHD-PAH) from the investigator's hospital.
- Trial name
- CHD-PAHCS (NCT03977428)
- Testing
- standard of care
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Wuhan Asia Heart Hospital
Pulmonary Arterial Hypertension
Safety, Tolerability, Pharmacokinetics and Efficacy of Two Different Rates of Subcutanous Remodulin® Dose Titration in Pulmonary Arterial Hypertension
This is an open-label, multicenter, parallel, randomized (1:1 Slow Dose Titration Group; Rapid Dose Titration Group), two-group study to evaluate the safety, tolerability, pharmacokinetics and efficacy of slow and rapid dose…
- Trial name
- NCT02893995
- Testing
- Slow Dose Titration Group of Subcutaneous Treprostinil, Rapid Dose Titration Group of Subcutaneous Treprostinil
- Where
- 10 sites in China
- Sponsor
- United Therapeutics
Pulmonary Hypertension, Pulmonary Embolism (Diagnosis)
China Pulmonary Vascular Disease Intervention Diagnosis and Management Study-right Heart Catheterization
Right heart catheterization(RHC) plays a crucial role in the diagnosis and treatment of pulmonary vascular diseases(PVD). In China, the lack of equipment and technical expertise has historically limited the implementation of RHC…
- Conditions
- Pulmonary Hypertension, Pulmonary Embolism (Diagnosis), Pulmonary Arterial Hypertension, Right Heart Catheterization
- Trial name
- CHA-RHC (NCT06954727)
- Testing
- No intervention; Observational study
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- China-Japan Friendship Hospital
Pulmonary Arterial Hypertension
Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument
SYMPHONY is prospective, multi-center, open-label, single-arm, Phase 3b psychometric validation study of the PAH-SYMPACT, a new quality of life questionnaire for patients with pulmonary arterial hypertension.
- Trial name
- NCT01841762
- Testing
- Macitentan
- Where
- 81 sites in United States
- Volunteers
- 284 people
- Sponsor
- Actelion
Arterial Hypertension (PAH)
Bioequivalence Study to Compare Selexipag 400 Microgram Film Coated Tablets Versus Uptravi® (Selexipag) 400 Microgram Film Coated Tablets
An open label, randomized, Three treatment, Three sequence, Three period, Three way crossover, single dose oral bioequivalence study to compare Selexipag 400 microgram film coated tablets versus Uptravi® (selexipag) 400 microgram…
- Trial name
- NCT07694128
- Testing
- Selexipag Film Coated Tablets (T1), Selexipag Film Coated Tablets (T2), Uptravi® (selexipag) film coated tablets
- Where
- India
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
Pulmonary Arterial Hypertension, Hypertension, Pulmonary
Safety And Efficacy Of Sildenafil In Children With Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a rare, progressive, and life-threatening disease. In many patients, the course of PAH is a steady deterioration and reduced life expectancy.
- Trial name
- NCT01642407
- Testing
- Sildenafil
- Where
- 5 sites in Japan
- Volunteers
- 6 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.